Department of Hematology and Oncology, Klinikum Augsburg, Germany.
Haematologica. 2013 Apr;98(4):518-25. doi: 10.3324/haematol.2012.070235. Epub 2012 Sep 14.
Based on molecular aberrations, in particular the NPM1 mutation (NPM1(mut)) and the FLT3 internal tandem duplication (Flt3-ITD), prognostic subgroups have been defined among patients with acute myeloid leukemia with normal karyotype. Whereas these subgroups are known to play an important role in outcome in first complete remission, and also in the indication for allogeneic stem cell transplantation, data are limited on their role after transplantation in advanced disease. To evaluate the role of molecular subgroups of acute myeloid leukemia with normal karyotype after allogeneic stem cell transplantation beyond first complete remission, we analyzed the data from 141 consecutive adults (median age: 51.0 years, range 18.4-69.3 years) who had received an allogeneic transplant either in primary induction failure or beyond first complete remission. A sequential regimen of cytoreductive chemotherapy (fludarabine, high-dose AraC, amsacrine) followed by reduced intensity conditioning (FLAMSA-RIC), was uniformly used for conditioning. After a median follow up of three years, overall survival from transplantation was 64 ± 4%, 53 ± 4% and 44 ± 5% at one, two and four years, respectively. Forty patients transplanted in primary induction failure achieved an encouraging 2-year survival of 69%. Among 101 patients transplanted beyond first complete remission, 2-year survival was 81% among patients with the NPM1(mut)/FLT3(wt) genotype in contrast to 43% in other genotypes. Higher numbers of transfused CD34(+) cells (hazard ratio 2.155, 95% confidence interval 0.263-0.964, P=0.039) and favorable genotype (hazard ratio 0.142, 95% confidence interval: 0.19-0.898, P=0.048) were associated with superior overall survival in multivariate analysis. In conclusion, patients with acute myeloid leukemia with normal karyotype can frequently be rescued after primary induction failure by allogeneic transplantation following FLAMSA-RIC. The prognostic role of NPM1(mut)/FLT3-ITD based subgroups was carried through after allogeneic stem cell transplantation beyond first complete remission.
基于分子异常,特别是 NPM1 突变(NPM1(mut))和 FLT3 内部串联重复(Flt3-ITD),在核型正常的急性髓系白血病患者中已经定义了预后亚组。虽然这些亚组在首次完全缓解和异体干细胞移植适应证中对预后具有重要作用,但关于它们在移植后晚期疾病中的作用的数据有限。为了评估核型正常的急性髓系白血病在异体干细胞移植后超过首次完全缓解的分子亚组的作用,我们分析了 141 例连续成人患者的数据(中位年龄:51.0 岁,范围 18.4-69.3 岁),他们在初次诱导失败或首次完全缓解后接受了异体移植。一种连续的细胞减少性化疗方案(氟达拉滨、高剂量阿糖胞苷、安吖啶),随后进行强度降低的条件预处理(FLAMSA-RIC),被统一用于条件预处理。中位随访 3 年后,从移植开始的总生存率分别为 1 年时 64 ± 4%、2 年时 53 ± 4%和 4 年时 44 ± 5%。40 例在初次诱导失败时移植的患者获得了令人鼓舞的 2 年生存率 69%。在 101 例超过首次完全缓解的患者中,NPM1(mut)/FLT3(wt)基因型患者的 2 年生存率为 81%,而其他基因型患者的 2 年生存率为 43%。在多变量分析中,更多的输注 CD34+细胞(风险比 2.155,95%置信区间 0.263-0.964,P=0.039)和有利的基因型(风险比 0.142,95%置信区间:0.19-0.898,P=0.048)与总生存率的提高相关。总之,核型正常的急性髓系白血病患者在初次诱导失败后,可以通过 FLAMSA-RIC 后进行异体移植来频繁挽救。在首次完全缓解后进行异体干细胞移植,NPM1(mut)/FLT3-ITD 为基础的亚组的预后作用得以延续。